In the present study, we define that CRISPR-Cas9n vectors plus its sgRNAs could efficiently suppress BIRC5 expression in vitro, which may enhance AML apoptosis and eventually improve outcomes in patients withleukemia. The gene discussed is BIRC5; the disease is acute myeloid leukemia.